The effect of retinoids on premalignant oral lesions: Focus on topical therapy

Cancer

Volumn 95, Issue 6, 2002, Pages 1258-1264

  Gorsky, Meir ^a   Epstein, Joel B ^b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Oral dysplasia; Oral leukoplakia; Retinoic acid; Retinoids; Vitamin A

Indexed keywords

ISOTRETINOIN; RETINOIC ACID; RETINOID; RETINOL; RETINOL DERIVATIVE;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; DRUG MECHANISM; DRUG RESPONSE; DYSPLASIA; HUMAN; LEUKOPLAKIA; MEDLINE; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SKIN TOXICITY; SYSTEMIC DISEASE; TOPICAL TREATMENT; TUMOR RECURRENCE;

ADMINISTRATION, TOPICAL; HUMANS; LEUKOPLAKIA, ORAL; PRECANCEROUS CONDITIONS; RETINOIDS; VITAMIN A;

EID: 0037105383     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10874     Document Type: Article

References (75)

1. Definition of leukoplakia and related lesions: An aid to studies on oral precancer
2. Oral white lesions with special reference to precancerous and tobacco related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994
3. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients
4. Studies on oral leukoplakia: A preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients
5. A prospective follow-up study of 570 patients with oral lichen planus: Persistence, remission and malignant association
6. Oral lichen planus: A benign lesion
7. Lichenoid dysplasia: A distinct histopathologic entity
8. Oral lichen planus: The evidence regarding potential malignant transformation
9. Comparative histopathological studies in oral lichen planus
10. Oral lichen planus: A potentially premalignant lesion
11. A prospective study of findings and management in 214 patients with oral lichen planus
12. Oral cancer development in patients with oral lichen planus
13. Oral lichen planus update: Clinical characteristics, treatment responses, and malignant transformation
14. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: Molecular evidence of incomplete resection
15. Increased genetic damage in oral leukoplakia from high risk sites: Potential impact on staging and clinical management
16. Use of allelic loss to predict malignant risk for low grade oral epithelial dysplasia
17. Frequent microsatellite alterations at chromosome 3p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
18. Molecular markers of the risk of oral cancer
19. Head and neck cancer
20. 2 laser treatment of oral leukoplakia
21. Surgical treatment of premalignant lesions of the oral mucosa
22. Risk of preneoplastic and neoplastic events in operated oral leukoplakias
23. Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa
24. Topical bleomycin for the treatment of dysplastic oral leukoplakia
25. Topical application of vitamin A to oral leukoplakia, a clinical case series
26. A study of the effect of high doses of vitamin A on oral leukoplakia (hyperkeratosis) including toxicity, liver function and skeletal metabolism
27. Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid
28. Retinoids, retinoid-responsive genes, cell differentiation, and cancer
29. Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic
30. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines
31. Retinoid sensitive cells and cells line
32. Vitamin A
33. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer
34. Retinoids in cancer prevention and therapy
35. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
36. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up
37. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its upregulation by isotretinoin
38. p53 and retinoid chemoprevention of oral carcinogenesis
39. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention
40. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis
41. Identification of a receptor for the morphogen retinoic acid
42. All-trans retinoic acid induced gene expression and growth inhibition in head and neck cancer cell lines
43. Chemoprevention of aerodigestive epithelial cancers
44. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: Modulation by 13-cis retinoic acid
45. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines
46. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines
47. Differential effects of retinoic acid and N-(4-hydroxyphenyl) retinamide on human head and neck squamous cell carcinoma cells
48. Therapeutic effect of N-(4-hydroxyphenyl) retinamide on N-methl-N-nitrosourea-induced rat mammary cancer
49. Prevention of local relapses and new localisatuions of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR) Preliminary results
50. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer
51. Mediation of N-4-hydroxyphenyl)retinimade-induced apoptosis in human cancer cells by different mechanisms
52. Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancer
53. Bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: A pilot study
54. 13-Cis-retinoic acid in the treatment of oral leukoplakia
55. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
56. Evaluation of a synthetic analog of vitamin A and beta carotene on the clinical and biologic markers in human premalignant oral lesions
57. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression
58. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
59. Initial experience in the treatment of oral leukoplakia with high-dose vitamin A and follow up 5-aminolevulinic acid induced protoporphyrin IX fluorescence
60. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis
61. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: An assessment
62. Response of oral leukoplakias to the administration of vitamin A
63. Studies in oral leukoplakias: III. Effects of vitamin A comparing clinical, histopathologic, cytologic and hematologic responses
64. The use of 13-cis-retinoic acid in the treatment of oral leukoplakia: Short-term observations
65. Retinoids as preventive and therapeutic anticancer agents (Part II)
66. Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid
67. Efficacy of etretinate (Tigason) in symptomatic oral lichen planus
68. Vitamin A derivatives in the prevention and treatment of human cancer
69. Topical tretinoin therapy and oral lichen planus
70. Topical application of isotretinoin gel improves oral lichen planus. A double-blind study
71. Effects of retinoids on oral leukoplakia
72. The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin
73. A modified classification and staging system for oral leukoplakia
74. Prevalence study of oral white lesions with special reference to a new definition of oral leukoplakia